Dec 8, 2020|

6618.HK: JD Health Celebrates Listing on HKEX


by Ella Kidron

JD Health listed on Hong Kong Stock Exchange (HKEX) on Dec. 8 at 9:30 am Beijing time with the ticker 6618.HK. The company held a celebration at headquarters in Beijing, virtually linked to the exchange in Hong Kong. Members of the and JD Health senior management and board, brand partners, financial and legal advisors, government representatives and employees all witnessed the ceremony.

According to HKEX’s announcement, JD Health is set at a price of HK $70.58 per share, and if the over-allotment option is not exercised, the net funds raised by the global offering will be about HK $26.5 billion.

In his remarks, Lijun Xin, CEO of JD Health, said: Led by Richard Liu, Chairman of, we started providing healthcare services in 2014 in order to solve industry pain points and create value for society. “2020 is not only an extraordinary year for everyone, but also a year in which JD Health creates social value and JD Health is recognized and understood by society.” Xin explained that in the face of COVID-19, JD Health immediately donated masks and medicines to Wuhan and joined forces with global supply chain partners to ensure the supply of epidemic prevention materials. In the span of three months, JD Health answered more than 10 million online consultation queries.

Members of the JD Health board, senior management of and JD Health all joined for the official sounding of the gong at opening bell.

From left to right:  Ling Li, Director of the Health Development Research Center of Peking University and board member of JD Health; Xingyao Chen, Chairman of the Board and president of New Hope Group and board member of JD Health; and Yayun Li, CCO of and board member of JD Health; Rui Yu, CHO of; Demin Han, academician of the Chinese Academy of Engineering and president of the China International Exchange and Promotive Assocition for Medical and Health Care (CPAM); Lijun Xin, CEO of JD Health; Sandy Xu, CFO of and board member of JD Health; Dr. Jon Liao, CSO of; Xiangmei Chen, Kidney disease expert and academician of the Chinese Academy of Engineering and Dong Cao, CFO of JD Health

JD Health is dedicated to creating a complete and comprehensive “Internet + healthcare” ecosystem. The company provides a wide assortment of high-quality pharmaceutical and healthcare products that cater to all aspects of users’ diverse healthcare needs. Strong fulfillment capabilities enable timely and secure delivery of medical products while holistic healthcare services to satisfy users’ needs across all aspects of the healthcare products and services.

According to the company’s prospectus, JD Health’s total revenue for in the first three quarters of 2020 was RMB 13.2 billion yuan, an increase of 77.1% YOY. The company had 80 million users as of Sept. 30, 2020, nearly double that of 2017.

Xin said: “JD Health will take the listing as an opportunity to do its utmost to promote the medical and health industry towards higher quality, more efficient, more inclusive and more sustainable development to provide convenient accessible and affordable medical and health products and services, and to be people’s chief health manager.”